Peroxisome proliferator-activated receptors (PPAR) are nuclear receptors that heterodimerize with the retinoid X receptor (RXR) and then modulate the function of many target genes. Three PPARs are known, , / and . The better known are PPAR and PPAR that may be activated by different synthetic agonists, although the endogenous ligands are unknown. PPAR is involved in fatty acid oxidation and expressed in liver, kidney and skeletal muscle, whereas PPAR is involved in fat cell differentiation, lipid storage and insulin sensitivity. However, both have been shown to be present in variable amounts in cardiovascular tissues, including the endothelium, smooth muscle cells, macrophages and the heart. The activators of PPAR (fibrates), and PPAR
Introduction
Peroxisome proliferator-activated receptors (PPARs) are nuclear factors initially shown to respond to xenobiotics with peroxisomal proliferation in the rodent liver [30] . Later they were demonstrated to modulate genes that regulate lipid and glucose metabolism {reviewed in ref. 40] . More recently, PPARs have been shown to participate in the regulation of cell growth and migration [36] , oxidant stress [15, 59] and inflammation [13] in the cardiovascular system. PPAR is found in tissues where fatty acid catabolism is important (liver, kidney, heart, and muscle) and is stimulated by natural ligands such as fatty acids and eicosanoids (eg.: leukotriene B 4 ), and by synthetic ligands, the lipid lowering fibrates [14] .
PPAR affects target genes that participate in -and -oxidation of fatty acids. PPAR / is expressed in many tissues [6, 34] . Recent evidence suggests that PPAR / is involved in fatty acid and lipid metabolism, particularly in skeletal muscle [9, 40, 60] . This may also occur in cardiovascular tissues [24] . PPAR controls adipocyte differentiation and lipid storage [60] and is accordingly highly expressed in adipose tissue. Through its effects on adipose tissue and skeletal muscle, PPAR regulates the action of insulin. Selective activators of PPAR are the insulin sensitizers thiazolidinediones or glitazones, such as troglitazone, pioglitazone and rosiglitazone.
PPARs have an N-terminal domain that regulates PPAR activity, a DNA binding domain that binds to the PPAR response element (PPRE) in the promoter region of target genes, a domain for a cofactor, and a C-terminal ligand-binding domain that determines ligand specificity [62] . PPARs are bound to co-repressor proteins when inactive. After stimulation by PPAR activators, PPARs dissociate from co-repressors and recruit co-activators, which include a PPAR-binding protein and the steroid receptor coactivator-1 [37] , and 4 heterodimerize with retinoid X receptors (RXR ). They then bind to PPRE in target genes to modulate gene transcription [27] . Gene regulation by this mechanism results in the action that PPARs have on carbohydrate and lipid metabolism (figure 1). Both PPAR and also exert numerous effects by interaction with different transcription factors to repress proinflammatory genes (figure 1). Whereas the effects on carbohydrate and lipid metabolism affect the cardiovascular system mainly through their impact on atherogenesis, the antiinflammatory and antioxidant actions of PPARs affect cardiovascular remodeling in many ways. Effects of PPARs on cardiovascular remodeling are the main subject of the present review, beyond their regulatory effects on glucose and lipid metabolism that have been reviewed recently [40] .
Vascular effects of PPAR alpha
PPAR and PPAR are expressed in the cardiovascular system [5] . PPAR are found in endothelial cells [28] , vascular smooth muscle cells (VSMC) [56] and in monocytes/macrophages [10] . The role that these nuclear factors play in the vasculature and the heart has been revealed over the past few years [40] . PPAR ligand docosahexanoic acid (DHA) was shown to have proapoptotic effects on cultured VSMCs [19] which were mediated by activation of p38 mitogen-activated protein kinase (MAP kinase) [21] . Antiinflammatory effects were demonstrated by the inhibition by PPAR ligands of interleukin (IL)-1 -induced production of IL-6 and prostaglandins, and expression of cyclooxygenase-2.
These effects occurred as a consequence of PPAR inhibition of signaling by the proinflammatory mediator nuclear factor (NF)-B and induction of apoptosis [10] .
Antagonism of signaling by NF-B was also demonstrated by other investigators [12, 46] . PPAR activators also down-regulated cytokine-induced genes, such as vascular cell 5 adhesion molecule (VCAM)-1 and tissue factor in endothelial cells [42] . PPAR -deficient mice demonstrated enhanced inflammatory responses to lipopolysaccharide (LPS) administration, and in these mice fibrates were unable to affect LPS-induced IL-6 [12] . The PPAR activator fenofibrate also reduced plasma concentrations of the cytokines interferonand tumor necrosis factor (TNF ) in hyperlipoproteinemia IIb patients [38] .
Because PPARs might antagonize angiotensin II (Ang II) effects, the action of the PPAR activator DHA was investigated in angiotensin II-infused rats [15] . DHA reduced Concomitantly, endothelial dysfunction typically found under Ang II infusion was prevented by DHA, together with reduction in NADPH oxidase-dependent superoxide anion formation.
Although these effects cannot be conclusively and unambiguously shown to be unrelated to BP reduction, in some models such as the DOCA-salt hypertensive rat, they have occurred in response to PPAR activators in absence of significant BP lowering [26] . This suggests that they are probably not dependent on reduction of BP.
Recent studies have elucidated some of the mechanisms involved in the beneficial effects of PPAR activation on endothelial function. Goya et al. demonstrated that fenofibrate increases endothelial nitric oxide synthase (eNOS) expression in bovine aortic endothelial cells. Interestingly this does not occur through effects on eNOS gene promoter activity but rather through increases in mRNA stability [25] .
Vascular effects of PPAR gamma
Like PPAR , PPAR has been reported to be present in the vasculature [40] and was demonstrated in endothelial cells [52] , VSMCs [20, 35] and in monocytes/macrophages [50] .
PPAR activators inhibited proliferation and migration of VSMCs [35, 36] . They enhanced the expression of PPAR in macrophages and inhibited expression of inducible nitric oxide synthase (iNOS), matrix metalloproteinase (MMP)-9 and scavenger receptor A. These effects of PPAR were mediated in part by inhibition of transcription factors AP-1, STAT and NF-B. PPAR activators inhibited expression of tumor necrosis factor (TNF) , interleukin (IL)-6, IL-1 [31] , iNOS, MMP-9 and scavenger receptor A in monocytes [49] . PPAR activators attenuated TNF-induced VCAM-1 and ICAM-1 expression in endothelial cells, and reduced monocyte/macrophage homing to atherosclerotic plaques in apoE-deficient mice [45] .
PPAR expression has indeed been demonstrated in human atherosclerotic plaques [48] . In DOCA-salt hypertensive rats, a hypertensive model associated with enhanced expression of preproendothelin (preproET)-1, BP increase was prevented in part by the PPAR activator rosiglitazone but not by the PPAR activator fenofibrate [26] . Both PPAR activators however abrogated the increase of preproET-1 mRNA in mesenteric blood vessels of these hypertensive rats, and prevented the hypertrophic remodeling typically found in DOCA-salt rats. Rosiglitazone but not fenofibrate prevented endothelial dysfunction, but both abrogated the enhanced production of reactive oxygen species that occurs in blood vessels in DOCA-salt hypertensive rats.
Spontaneously hypertensive rats (SHR) exhibit insulin resistance that has been associated with a mutation of cd36, which encodes for a fatty acid translocase. Insulin resistance thus results in decreased fatty acid translocation [1] . cd36 is a target of PPAR . It has been speculated that expression of PPARs could be decreased in blood vessels of SHR, which would exacerbate proliferation, migration, inflammation and fibrosis, as found in this hypertensive model. Indeed, human mutations of PPAR have been associated with diabetes, insulin resistance and hypertension, all of which are accompanied by vascular disease [4] .
However, rather than decreased expression of PPAR and in blood vessels and cultured VSMC from SHR, their expression was increased [20] . This may result from a feedback response to the decreased activity of the mutant cd36 of SHR.
Mechanisms whereby PPAR activation improves endothelial function were investigated by Calnek et al [8] . These authors demonstrated that PPAR ligands, 15d-PGJ 2 or ciglitazone increased NO release by porcine and human aortic endothelial cells. PPAR 8 activation did not increase eNOS expression. Overexpression of PPAR or treatment with 9-cis retinoic acid also enhanced NO release. Neither 15d-PGJ 2 nor ciglitazone altered eNOS mRNA. Thus, PPAR ligands stimulated NO release from endothelial cells through a transcriptional mechanism unrelated to eNOS expression [8] .
Many studies have pointed toward an inhibitory role of PPARs in atherogenesis [40] .
The effect of rosiglitazone treatment on mechanisms involved in the initial stages of atherogenesis was evaluated in rabbits fed a high cholesterol diet [59] . Treatment with rosiglitazone enhanced the down-regulated PPAR expression, improved endotheliumdependent vasodilatation, suppressed gp91phox and iNOS expression, reduced superoxide and total NO production, and inhibited nitrotyrosine formation. The endothelial protective effects of PPAR activators may reduce leukocyte accumulation in the vascular wall, contributing to anti-atherosclerotic effects.
Ishibashi et al. [29] studied effects of pioglitazone in rats receiving N -nitro-Larginine methyl ester (L-NAME) to inhibit eNOS. The PPAR activator pioglitazone did not affect blood pressure, the metabolic state or serum NO levels, but prevented L-NAME- Rosiglitazone has also been shown to reduce endothelial markers such as E-selectin and von Willebrand factor in non diabetic CAD subjects [54] . Eighty-four patients with In a study of 136 Japanese type 2 diabetic subjects, pioglitazone was administered for 3 months and changes in glycolipid metabolism, plasma high-sensitivity CRP, leptin, adiponectin, and pulse wave velocity (PWV, a parameter that increases with the stiffness of blood vessels and is indicative of the presence of vascular injury) were evaluated to investigate the relationship between the anti-atherogenic and anti-diabetic effects of pioglitazone [51] . Pioglitazone treatment improved glucose metabolism, and increased plasma adiponectin concentrations, and decreased CRP and PWV. Treatment with pioglitazone was associated with a low CRP and PWV independently of changes in carbohydrate metabolism. Thus, the PPAR agonist exerted anti-atherogenic effects independent of its anti-diabetic action by lowering CRP that contributes to vascular injury, and the stiffness of blood vessels, which is a measure of vascular disease and contributes to enhance pulse pressure, another risk factor for vascular events.
Cardiac effects of PPARs
PPAR regulates cardiac energy and lipid metabolism and plays a role in mitochondrial fatty acid -oxidation, which is critical for fuel generation in the heart [7] . It serves as a molecular 'lipostat' through the induction of target genes involved in fatty acid metabolism [22] . PPAR controls myocardial lipid metabolism through activation of transcription of carnitine palmitoyltransferase I (CPT I) [7] . In PPAR -null mice the capacity for constitutive myocardial -oxidation of medium and long-chain fatty acids was markedly reduced [68] . Constitutive -oxidation of very long chain fatty acids such as lignoceric acid was unaffected in PPAR -deficient mice. This suggests that PPAR is not involved in the constitutive expression of enzymes that mediate -oxidation.
During cardiac hypertrophy PPAR is inhibited [3] , which reduces the capacity of hypertrophied myocytes to metabolize myocardial lipids, resulting in intracellular fat accumulation. PPAR activators inhibited cardiac expression of TNF and NF-B induced by LPS [57] . Fenofibrate reduced preproET-1 mRNA expression and collagen type I and type III mRNA, associated with decreased in interstitial and perivascular cardiac fibrosis after pressure-overload induced by abdominal aortic banding [44] , probably through 13 suppression of AP-1-mediated preproET-1 gene activation. Additionally, fenofibrate reduced cardiac hypertrophy and inflammation, associated with an increase in the anti-inflammatory cytokine IL-10 [39] . Fenofibrate had beneficial effects on inflammation and collagen deposition in the heart of Ang II-infused rats [16] . NF-B activity, VCAM-1, PECAM, ICAM-1 and ED-1 (macrophage antigen) expression were all decreased, and AT 1 receptors down-regulated and AT 2 receptors upregulated, which may be considered a beneficial change since AT 1 are pro-hypertrophic, proinflammatory and pro-fibrotic, whereas AT 2 are generally shown to exert opposite effects.
The role of PPAR in the heart is less clear than that of PPAR . Expression of PPAR in the heart is very low [33] . PPAR activators inhibited hypertrophy and brain natriuretic peptide expression in cultured cardiomyocytes [70] . Aortic banding induced enhanced cardiac hypertrophy in heterozygous PPAR -deficient mice [2] , suggesting an inhibitory effect of PPAR on cardiac growth. Pioglitazone, however, blunted myocardial hypertrophy in both wild-type and PPAR -/-mice, suggesting an effect independent of activation of PPAR . Angiotensin II-induced gene expression and cardiomyocyte hypertrophy were attenuated in vitro by thiazolidinediones. These data suggest that PPAR inhibits cardiac hypertrophy. In diabetic rats, PPAR improved left ventricular diastolic function and decreased collagen accumulation [61, 72] , and also protected the myocardium from ischemic injury [53, 71] . On the other hand, PPAR activators may trigger an aggravation of congestive heart failure [66, 69] , which is counterintuitive with respect to the cardiovascular preventive potential of these drugs. This appears to be mainly due to fluid retention as a consequence of their insulinomimetic action on the kidney, rather than a negative inotropic effect. Thus, caution has been urged in the use of thiazolidinediones in diabetic patients with advanced heart failure [43] , even though these agents may have cardiovascular protective properties in patients with less advanced cardiovascular disease.
The hypertrophic heart typically experiences an increase in glucose utilization and 
